Mutations in non-structural 5A and rapid viral response to pegylated             interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy             in patients with genotype 1b chronic hepatitis C.

doi:10.3892/ijmm.2012.1093

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.

International journal of molecular medicine - 1 Nov 2012

Yano Yoshihiko, Seo Yasushi, Miki Akira, Saito Masaya, Kato Hirotaka, Hamano Ken-Ichi, Oya Manabu, Ouchi Sachiko, Fujisawa Takashi, Yamada Hajime, Yamashita Yukimasa, Tani Satoshi, Hirohata Shigeya, Yoon Seitetsu, Kitajima Naoto, Kitagaki Kazunari, Kawara Akira, Nakashima Takatoshi, Yu Hosai, Maeda Tetsuo, Azuma Takeshi, El-Shamy Ahmed, Hotta Hak, Hayashi Yoshitake

Abstract excerpt

For patients chronically infected with hepatitis C virus (HCV), mutations in the non-structural 5A (NS5A) gene are important predictive factors for the response to interferon (IFN) therapy. In the present study, factor analysis of the therapeutic response of patients following pegylated IFN and ribavirin combination therapy was assessed in a multicenter study. Chronic HCV-infected patients with genotype 1b and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Patient Compliance

Share to Polyethylene Glycols

Share to Ribavirin

Share to Viral Nonstructural Proteins

Source

Open in PubMed

Identifiers

PMID: 22899224
DOI: 10.3892/ijmm.2012.1093

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.PMID 22899224Read ↗

Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNα-2a/RBV combination therapy in Azerbaijani patients.Semantic proximity Read ↗

Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy.Semantic proximity Read ↗

Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy.Semantic proximity Read ↗

Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study.Semantic proximity Read ↗

Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin.Semantic proximity Read ↗

Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection.Semantic proximity Read ↗

Biochemical response to interferon therapy correlates with interferon sensitivity-determining region in hepatitis C virus genotype 1b infection.Semantic proximity Read ↗

Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection.Semantic proximity Read ↗

Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.Semantic proximity Read ↗

Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy.Semantic proximity Read ↗

Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy.Semantic proximity Read ↗

Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon-α 2b and ribavirin) for genotype 1b chronic hepatitis C: The Kobe Hepatitis Therapeutic Group.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.